Linear IgA bullous dermatosis induced by angiotensin receptor antagonists [4]

American Journal of Medicine

Volumn 114, Issue 2, 2003, Pages 163-164

  Peña Penabad, Carmen ^a   Rodríguez Lozano, Jesús ^a   Del Pozo, Jesús ^a   García Silva, Jesús ^a   Fonseca, Eduardo ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMPICILLIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETAMETHASONE; CANDESARTAN; CAPTOPRIL; CEFAMANDOLE; CEFTRIAXONE; CYCLOSPORIN; DEFLAZACORT; DICLOFENAC; EPROSARTAN; FUROSEMIDE; FUSIDIC ACID; GAMMA INTERFERON; GEMCITABINE; GLIBENCLAMIDE; GLIMEPIRIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; INTERLEUKIN 2; IODINE; LITHIUM; METRONIDAZOLE; PENICILLIN G; PHENYTOIN; PIROXICAM; RIFAMPICIN; UNINDEXED DRUG; VANCOMYCIN;

AGED; ANGIONEUROTIC EDEMA; ASTHENIA; BULLOUS SKIN DISEASE; CASE REPORT; CLINICAL FEATURE; DIABETIC ANGIOPATHY; DIAPHORESIS; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LETTER; MALE; NAUSEA; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PRIORITY JOURNAL; RASH; SKIN BIOPSY; URTICARIA;

EID: 0037313960     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01422-5     Document Type: Letter

References (6)

1. Baden L.A., Apovian C., Imber M.J., Dover J.S. Vancomycin induced linear bullous IgA dermatosis. Arch Dermatol. 124:1988;1186-1188.
2. Nousari H.C., Kimyai-Asadi A., Caeiro J.P., Anhalt G.J. Clinical, demographic and immunohistologic features of vancomycin-induced linear IgA bullous disease of the skin. Report of 2 cases and review of the literature. Medicine (Baltimore). 78:1999;1-8.
3. Paul C., Prost C. Drug-induced linear IgA disease target antigens are heterogenous. Br J Dermatol. 136:1997;406-411.
4. Friedman I.S., Rudikoff D., Phelps R.G., Sapadin A.N. Captopril-triggered linear IgA bullous dermatosis. Int J Dermatol. 37:1998;608-612.
5. See S., Stirling A.L. Candesartan cilexetil an angiotensin II-receptor blocker. Am J Health Syst Pharm. 57:2000;739-746.
6. Naranjo C.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 30:1981;239-245.